Healthcare Services

Epithelial Ovarian Cancer Market Future Outlook Showing Expansion Toward $5.03 Billion by 2030

April 1, 2026April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Epithelial Ovarian Cancer Market During The Forecast Period 2026–2030?

The market for epithelial ovarian cancer has experienced rapid growth in its size over recent years. It is anticipated to expand from $2.41 billion in 2025 to $2.8 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 16.2%. The historical period’s expansion can be attributed to several factors, including the prevalence of late-stage diagnoses, the application of chemotherapy, an aging female demographic, advancements in oncology infrastructure, and the broadening of clinical trials.

The epithelial ovarian cancer market is anticipated to undergo significant expansion in the coming years. It is projected to achieve a value of $5.03 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 15.7%. The drivers behind this growth throughout the forecast period include the increasing adoption of precision oncology, advancements in biomarker-based diagnostics, the development and expansion of immunotherapy pipelines, heightened awareness regarding early screening, and better survival outcomes for patients. Prominent trends expected during the forecast period involve the growing acceptance of targeted therapies, an increase in the utilization of combination treatment regimens, enhancements in early diagnostic technologies, broader applications of immunotherapy, and a strong focus on personalized oncology care.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20778&type=smp

Which Economic Or Industry Drivers Are Impacting The Epithelial Ovarian Cancer Market?

The expanding occurrence of ovarian cancer is anticipated to fuel the expansion of the epithelial ovarian cancer market in the coming years. Ovarian cancer originates in the ovaries, predominantly impacting the epithelial cells covering their surface. This rise in ovarian cancer cases is largely attributed to an aging populace, enhanced awareness, and elevated detection rates, alongside genetic predispositions and lifestyle choices. Treatment for epithelial ovarian cancer is essential to tackle this prevalent and aggressive type of the disease, aiming to target malignant cells for better survival and patient results. For example, data from February 2024, provided by the World Ovarian Cancer Coalition, a non-profit organization based in Canada, projects that by 2050, the worldwide count of women diagnosed with ovarian cancer will grow by more than 55%, totaling 503,448 individuals. The yearly fatalities attributed to ovarian cancer are forecasted to climb to 350,956, marking an almost 70% surge compared to 2022 figures. Consequently, the growing incidence of ovarian cancer is set to propel the epithelial ovarian cancer market ahead.

What Market Segments Are Evaluated Within The Epithelial Ovarian Cancer Market?

The epithelial ovarian cancer market covered in this report is segmented –

1) By Type Of Treatment: Chemotherapy, Targeted Therapy, Immunotherapy, Hormonal Therapy, Surgery

2) By Drug Class: Platinum-Based Chemotherapy Drugs, Poly (ADP-ribose) Polymerase Inhibitors, Bevacizumab, Chemotherapeutic Agents

3) By Stage Of Cancer: Early Stage, Advanced Stage

4) By Diagnosis Method: Imaging, Biopsy, Blood Tests

5) By End User: Hospitals, Clinics, Diagnostic Laboratories

Subsegments:

1) By Chemotherapy: Platinum-Based Chemotherapy, Non-Platinum Chemotherapy, Combination Chemotherapy

2) By Targeted Therapy: Monoclonal Antibodies, PARP Inhibitors, Angiogenesis Inhibitors

3) By Immunotherapy: Checkpoint Inhibitors, Cancer Vaccines, Adoptive T-Cell Therapy

4) By Hormonal Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Progestins

5) By Surgery: Debulking Surgery, Oophorectomy, Hysterectomy

What Key Trends Are Influencing The Development Of The Epithelial Ovarian Cancer Market?

Key companies operating within the epithelial ovarian cancer market are concentrating on developing innovative treatment options, such as FRa-directed antibody-drug conjugates (ADCs). These therapies aim to specifically target folate receptor-alpha overexpressed on cancer cells, delivering potent cytotoxic agents while minimizing harm to healthy tissues. An FRa-directed antibody-drug conjugate (ADC) is defined as a targeted cancer therapy that links an antibody specific to the folate receptor-alpha (FRa) to a cytotoxic drug, ensuring the drug is delivered directly to cancer cells expressing this receptor. For instance, in November 2024, AbbVie Inc., a US-based biopharmaceutical company, obtained European Commission approval for ELAHERE (mirvetuximab soravtansine). This targeted treatment is intended for adult patients with folate receptor-alpha (FRa) positive, platinum-resistant, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. ELAHERE presents a new, effective treatment option for patients who have received up to three prior systemic regimens. It targets a biomarker identified in approximately one-third of ovarian cancer patients, contributing to an enhanced chance of survival and an improved quality of life. The approval further includes a companion diagnostic tool to identify suitable patients.

Who Are The Top Market Participants Influencing The Epithelial Ovarian Cancer Market?

Major companies operating in the epithelial ovarian cancer market are Pfizer Inc., Johnson & Johnson Services Inc., F. Hoffmann-La Roche AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Bristol-Myers Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc, Eli Lilly and Company, Boehringer Ingelheim GmbH, Merck KGaA, Siemens Healthineers AG, Quest Diagnostics Incorporated, Eisai Co. Ltd., Genentech Inc., Qiagen N.V., Myriad Genetics Inc., Clovis Oncology Inc., Fujirebio Diagnostics Inc.

Read the full epithelial ovarian cancer market report here:

https://www.thebusinessresearchcompany.com/report/epithelial-ovarian-cancer-global-market-report

What Are The Top-Performing Regions Within The Epithelial Ovarian Cancer Market?

North America was the largest region in the epithelial ovarian cancer market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the epithelial ovarian cancer market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Epithelial Ovarian Cancer Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=20778&type=smp

Browse Through More Reports Similar to the Global Epithelial Ovarian Cancer Market 2026, By The Business Research Company

Ataxia Global Market Report

https://www.thebusinessresearchcompany.com/report/ataxia-global-market-report

Progressive Ataxia And Weakness Disorders Global Market Report

https://www.thebusinessresearchcompany.com/report/progressive-ataxia-and-weakness-disorders-global-market-report

Dyslexia Treatment Global Market Report

https://www.thebusinessresearchcompany.com/report/dyslexia-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795